Intranasally administered S-MGB-364 displays antitubercular activity and modulates the host immune response to Mycobacterium tuberculosis infection
暂无分享,去创建一个
Fraser J. Scott | F. Brombacher | R. Guler | N. Kieswetter | C. Suckling | Fraser J Scott | K. Carter | J. Cross | M. Ozturk | Lerato Hlaka | J. E. Chia | Leah M. C. McGee | Izaak Tyson-Hirst | Rebecca Beveridge | R. J. Nichol
[1] N. Tucker,et al. Novel antibiotic mode of action by repression of promoter isomerisation , 2021, bioRxiv.
[2] E. Touitou,et al. Phospholipid Vesicles for Dermal/Transdermal and Nasal Administration of Active Molecules: The Effect of Surfactants and Alcohols on the Fluidity of Their Lipid Bilayers and Penetration Enhancement Properties , 2020, Molecules.
[3] B. Mishra,et al. Granulocytes act as a niche for Mycobacterium tuberculosis growth , 2020, Mucosal Immunology.
[4] Fraser J. Scott,et al. Novel Minor Groove Binders Cure Animal African Trypanosomiasis in an in Vivo Mouse Model. , 2019, Journal of medicinal chemistry.
[5] D. Zak,et al. Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases , 2018, Mucosal Immunology.
[6] Fraser J. Scott,et al. Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacy , 2017, The Journal of antimicrobial chemotherapy.
[7] M. Barrett,et al. An evaluation of Minor Groove Binders as anti-fungal and anti-mycobacterial therapeutics. , 2017, European journal of medicinal chemistry.
[8] S. Khader,et al. Cytokines and Chemokines in Mycobacterium tuberculosis Infection , 2016, Microbiology spectrum.
[9] Jay W. Shin,et al. Batf2/Irf1 Induces Inflammatory Responses in Classically Activated Macrophages, Lipopolysaccharides, and Mycobacterial Infection , 2015, The Journal of Immunology.
[10] Harukazu Suzuki,et al. IL-4Rα-Dependent Alternative Activation of Macrophages Is Not Decisive for Mycobacterium tuberculosis Pathology and Bacterial Burden in Mice , 2015, PloS one.
[11] S. Ekins,et al. Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison. , 2014, Biochemical and biophysical research communications.
[12] M. Barrett,et al. Minor groove binders as anti-infective agents. , 2013, Pharmacology & therapeutics.
[13] G. H. Coombs,et al. The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[14] Mark A. Miller,et al. Visualization of Murine Intranasal Dosing Efficiency Using Luminescent Francisella tularensis: Effect of Instillation Volume and Form of Anesthesia , 2012, PloS one.
[15] A. Nakamura,et al. Recent developments in the use of γ -H2AX as a quantitative DNA double-strand break biomarker , 2011, Aging.
[16] B. Nyström,et al. Nanobead-based interventions for the treatment and prevention of tuberculosis , 2010, Nature Reviews Microbiology.
[17] Jean-Jacques Helesbeux,et al. Antimicrobial lexitropsins containing amide, amidine, and alkene linking groups. , 2007, Journal of medicinal chemistry.
[18] R. Snyder,et al. Toward a greater appreciation of noncovalent chemical/DNA interactions: Application of biological and computational approaches , 2005, Environmental and molecular mutagenesis.
[19] Hans Lennernäs,et al. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. , 2003, Journal of pharmaceutical sciences.
[20] R. Snyder,et al. EVIDENCE FOR AND ROLE OF THE DIMETHYLAMINO GROUP IN TAMOXIFEN DNA INTERCALATION IN INTACT CHINESE HAMSTER V79 CELLS , 2002, Drug and chemical toxicology.
[21] J. Campbell,et al. Mutagenicity of electrophilic N-acyloxy-N-alkoxyamides. , 2001, Mutation research.